Amplification-free miRNA detection with CRISPR/Cas12a system based on fragment complementary activation strategy

imaging, effectively recognizing tumor cells. The FCAS not only broadens the scope of CRISPR/Cas12a system target identification but also unlocks the potential for in-depth studies of CRISPR technology in many diagnostic settings.